Further investigation is therefore warranted to explore whether targeting the LySR pathway to boost lysosomal function and reduce proteotoxicity may also provide protection against normal ageing and neurodegenerative diseases in other organisms in vivo. The gene discussed is KARS1; the disease is neurodegenerative disease.